CN114939161B - Application of PD-1 antibody in preparation of medicine for treating tendon injury - Google Patents
Application of PD-1 antibody in preparation of medicine for treating tendon injury Download PDFInfo
- Publication number
- CN114939161B CN114939161B CN202210724451.4A CN202210724451A CN114939161B CN 114939161 B CN114939161 B CN 114939161B CN 202210724451 A CN202210724451 A CN 202210724451A CN 114939161 B CN114939161 B CN 114939161B
- Authority
- CN
- China
- Prior art keywords
- antibody
- tendon
- injury
- medicament
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to the technical field of medicines, discloses an application method of a PD-1 antibody in preparing a medicine for treating tendon injury, and particularly discloses an application of the PD-1 antibody or an antigen binding fragment derivative thereof in preparing a medicine for preventing and/or treating sports injury. The invention discloses the application of a PD-1 antibody or an antigen binding fragment derivative thereof in preventing and/or treating sports injury for the first time, the PD-1 antibody or the antigen binding fragment derivative thereof can obviously improve the elastic modulus of injured tissues, reduce the calcified volume of the injured tissues, reduce the formation of ectopic ossification of the injured tissues, and achieve the purpose of treating sports injury by inhibiting the formation of calcified tissues of the injured tissues, improving the biomechanical properties of the injured tissues and/or reducing the formation of ectopic ossification of the injured tissues, so that the PD-1 antibody or the antigen binding fragment derivative thereof can be used for preparing medicines for preventing and/or treating sports injury, and is convenient to be applied to clinical and daily health care after tendon injury.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an application of a PD-1 antibody in preparation of a medicine for treating tendon injury.
Background
Tendons are dense connective tissues connecting muscles and bones, and transmit contraction force of muscles to bones to support body movement. In the case of overuse or age deterioration of tendons, tendon injuries occur to various degrees, and thus are very common in the daily life and exercise fields. Calcification of tendons is a common and serious complication of tendon injury and also a manifestation of chronic functional and structural disorders resulting from tendon injury. The incidence of calcification after achilles tendon rupture surgery is as high as 14% -62%, and symptoms such as pain, tendon weakness, local edema and limited activity can be caused.
At present, the pathogenesis of tendon calcification is not clear, so that no clear medicament for preventing and treating tendon calcification exists. Once formed, the calcification of the tendon cannot be eliminated by conservative treatment methods such as medicines, and can only be relieved by some conservative treatment methods such as local injection of non-steroidal anti-inflammatory drugs, glucocorticoids or local shock wave treatment, and in severe cases, the calcification focus can only be eliminated by surgery, but the effect is limited. The treatment effect of shock wave treatment on tendon calcification is uncertain, although some researches confirm the effectiveness of the treatment, the research also shows that no obvious beneficial effect exists, the mechanism of shock wave treatment is uncertain, and under the current condition, the treatment method as a physical treatment method for relieving symptoms is an anecdotal choice, and a new safer and more effective treatment method is expected to appear in clinic. Although nonsteroidal anti-inflammatory drugs and glucocorticoids provide some symptomatic relief and local inflammation in the treatment of calcification of tendons, they may adversely affect the self-healing and homeostasis of tendons when used as a conservative treatment. Research shows that glucocorticoid can induce tendon cell to generate fibro-cartilage tissue and induce spinal ligament cell to generate osteogenic differentiation, so it is prudent to select glucocorticoid for conservative treatment. After calcification has formed, the analgesic effect can only be achieved with non-steroidal anti-inflammatory drugs. Whether non-steroidal anti-inflammatory drugs adversely affect the self-healing and homeostasis of tendons remains controversial. Studies show that the non-steroidal anti-inflammatory drug can inhibit the proliferation and migration of tendon cells in vitro, and animal experiments also find that the non-steroidal anti-inflammatory drug can damage the biomechanical strength of the tendon. Therefore, the development of a drug for preventing and/or treating calcification formation of tendon after tendon injury and improving the biomechanical strength of tendon is a scientific problem to be solved.
The apoptosis receptor (Programmed Cell Death 1, PD-1) antibody initially serves as an immune checkpoint molecule that down-regulates a variety of immune Cell activities during the immune response to prevent damage to autoimmune tissue, but also thereby impairs the killing function of the autoimmune system against tumor cells or pathogens. The PD-1 antibody can improve the immune tolerance of the body caused by tumors or various chronic infections and improve the autoimmune activity by combining with the antibody. At present, the PD-1 antibody is used as an immune check point inhibitor, is applied to diseases such as non-small cell lung cancer, melanoma, head and neck tumors, breast cancer, liver cancer, digestive tract tumors and the like, has good clinical effect, and gradually enters clinical treatment tests of infectious diseases such as HIV, viral hepatitis, septicemia and the like.
The main effects of the PD-1 antibody reported in the prior literature are as follows: (1) Treating melanoma, squamous non-small cell lung cancer, hodgkin lymphoma, hepatocellular carcinoma, and urothelial cancer; (2) treating viral hepatitis; and (3) treating sepsis, and improving the survival rate of patients. Until now, there is no report about the prevention of calcification formation and improvement of biomechanical strength of tendon after tendon injury by PD-1 antibody, and it cannot be concluded from the known properties of PD-1 antibody whether it has the effect of preventing calcification formation and improvement of biomechanical strength of tendon after tendon injury.
Disclosure of Invention
The object of the first aspect of the present invention is to provide the use of a PD-1 antibody or an antigen-binding fragment derivative thereof for the preparation of a medicament for the prevention and/or treatment of sports injuries.
The second aspect of the present invention is directed to the use of a PD-1 antibody or an antigen-binding fragment derivative thereof for the manufacture of a medicament for inhibiting the formation of calcification in damaged tissue.
In a third aspect, the present invention is directed to the use of a PD-1 antibody or an antigen-binding fragment derivative thereof for the manufacture of a medicament for improving the biomechanical properties of damaged tissue.
The fourth aspect of the present invention is directed to the use of a PD-1 antibody or an antigen-binding fragment derivative thereof for the manufacture of a medicament for inhibiting ectopic ossification after tissue damage.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
in a first aspect of the invention, there is provided the use of PD-1, or an antigen-binding fragment derivative thereof, in the manufacture of a medicament for the prevention and/or treatment of sports injuries.
Preferably, the sports injury comprises at least one of acute injury, chronic injury; further acute injury.
Preferably, the athletic injury comprises at least one of tendon injury, ligament injury; further tendon injury.
Preferably, the tendon injury comprises at least one of rotator cuff injury, biceps brachii longus tendon injury, triceps brachii tendon injury, adductor femoris tendon injury, iliotibial band injury, quadriceps tendon injury, patellar tendon rupture, patellar tendon end disease, achilles tendon injury; further achilles tendon injury.
Preferably, the ligament injury comprises at least one of an elbow joint surrounding ligament injury, a knee joint surrounding ligament injury, and a cruciate ligament injury.
Preferably, the antibody or antigen binding fragment thereof is selected from the group consisting of Fab, fab ', F (ab') 2 Fd, fv, dAb, complementarity determining region fragment, single chain antibody, humanized antibody, chimeric antibody or diabody.
Preferably, the medicament achieves the purpose of treating and/or preventing sports injuries by inhibiting the formation of calcifications in the injured tissue, improving the biomechanical properties of the injured tissue and/or reducing the formation of ectopic ossification of the injured tissue.
Preferably, the medicament further comprises one or more pharmaceutically acceptable excipients.
Preferably, the pharmaceutically acceptable auxiliary material comprises at least one of a sustained release agent, an excipient, a filler, a binder, a wetting agent, a disintegrating agent, an absorption enhancer, a surfactant and a lubricant.
Preferably, the dosage form of the medicament comprises at least one of a solid formulation, a liquid formulation and a semi-solid formulation.
Preferably, the medicament comprises at least one of tablets, capsules, granules, pills, dropping pills, liquid preparations, soft extracts, suspending agents, dispersing agents, syrups, suppositories, gels, aerosols and patches.
In a second aspect of the invention, there is provided the use of a PD-1 antibody, or an antigen-binding fragment derivative thereof, in the manufacture of a medicament for inhibiting the formation of calcification in damaged tissue.
Preferably, the tissue comprises at least one of a tendon, a ligament; further a tendon.
Preferably, the tendon comprises at least one of achilles tendon, rotator cuff, supraspinatus; further the achilles tendon.
Preferably, the ligament comprises at least one of a ligament surrounding the elbow joint, a ligament surrounding the knee joint, and a cruciate ligament.
Preferably, the antibody or antigen binding fragment thereof is selected from the group consisting of Fab, fab ', F (ab') 2 Fd, fv, dAb, a complementarity determining region fragment, a single chain antibody, a humanized antibody, a chimeric antibody, or a diabody.
Preferably, the medicament further comprises one or more pharmaceutically acceptable excipients.
Preferably, the pharmaceutically acceptable adjuvant comprises at least one of sustained release agent, excipient, filler, binder, wetting agent, disintegrant, absorption enhancer, surfactant, and lubricant.
Preferably, the dosage form of the medicament comprises at least one of a solid formulation, a liquid formulation, a semi-solid formulation.
Preferably, the medicament comprises at least one of tablets, capsules, granules, pills, dropping pills, liquid preparations, soft extracts, suspending agents, dispersing agents, syrups, suppositories, gels, aerosols and patches.
In a third aspect of the invention, there is provided the use of a PD-1 antibody or antigen-binding fragment derivative thereof in the manufacture of a medicament for improving the biomechanical properties of damaged tissue.
Preferably, the improvement in the biomechanical properties of the damaged tissue is an increase in the elastic modulus of the damaged tissue.
Preferably, the tissue comprises at least one of a tendon, a ligament; further a tendon.
Preferably, the tendon comprises at least one of achilles tendon, rotator cuff, supraspinatus; further the achilles tendon.
Preferably, the ligament comprises at least one of a ligament surrounding an elbow joint, a ligament surrounding a knee joint, and a cruciate ligament.
Preferably, the antibody or antigen binding fragment thereof is selected from the group consisting of Fab, fab ', F (ab') 2 Fd, fv, dAb, a complementarity determining region fragment, a single chain antibody, a humanized antibody, a chimeric antibody, or a diabody.
Preferably, the medicament further comprises one or more pharmaceutically acceptable excipients.
Preferably, the pharmaceutically acceptable adjuvant comprises at least one of sustained release agent, excipient, filler, binder, wetting agent, disintegrant, absorption enhancer, surfactant, and lubricant.
Preferably, the dosage form of the medicament comprises at least one of a solid formulation, a liquid formulation, a semi-solid formulation.
Preferably, the medicament comprises at least one of tablets, capsules, granules, pills, dripping pills, liquid preparations, soft extracts, suspending agents, dispersing agents, syrups, suppositories, gels, aerosols and patches.
In a fourth aspect of the invention, there is provided the use of a PD-1 antibody or an antigen-binding fragment derivative thereof in the manufacture of a medicament for inhibiting the formation of ectopic ossification after tissue injury.
Preferably, the tissue comprises at least one of a tendon, a ligament; further a tendon.
Preferably, the tendon comprises at least one of achilles tendon, rotator cuff, supraspinatus; further the achilles tendon.
Preferably, the ligament comprises at least one of a ligament surrounding an elbow joint, a ligament surrounding a knee joint, and a cruciate ligament.
Preferably, the antibody or antigen binding fragment thereof is selected from the group consisting of Fab, fab ', F (ab') 2 Fd, fv, dAb, complementarity determining region fragment, single chain antibody, humanized antibody, chimeric antibody or diabody.
Preferably, the medicament further comprises one or more pharmaceutically acceptable excipients.
Preferably, the pharmaceutically acceptable adjuvant comprises at least one of sustained release agent, excipient, filler, binder, wetting agent, disintegrant, absorption enhancer, surfactant, and lubricant.
Preferably, the dosage form of the medicament comprises at least one of a solid formulation, a liquid formulation, a semi-solid formulation.
Preferably, the medicament comprises at least one of tablets, capsules, granules, pills, dripping pills, liquid preparations, soft extracts, suspending agents, dispersing agents, syrups, suppositories, gels, aerosols and patches.
The invention has the beneficial effects that:
the invention discloses the application of a PD-1 antibody or an antigen binding fragment derivative thereof in preventing and/or treating sports injury for the first time, the PD-1 antibody or the antigen binding fragment derivative thereof can obviously improve the elastic modulus of injured tissues, reduce the calcified volume of the injured tissues, reduce the formation of ectopic ossification of the injured tissues, and achieve the purpose of treating sports injury by inhibiting the formation of calcification of the injured tissues, improving the biomechanical performance of the injured tissues and/or reducing the formation of ectopic ossification of the injured tissues, so that the PD-1 antibody or the antigen binding fragment derivative thereof can be used for preparing a medicament for preventing and/or treating sports injury, and is convenient to be applied to clinical and daily health care after tendon injury.
Drawings
FIG. 1 is a graph of the effect of PD-1 antibody on biomechanical parameters following injury to a ruptured achilles tendon in mice; wherein A is a graph showing the influence of the PD-1 antibody on the elastic modulus of the mouse achilles tendon after rupture injury, B is a graph showing the influence of the PD-1 antibody on the cross-sectional area of the mouse achilles tendon after rupture injury, and C is a graph showing the influence of the PD-1 antibody on the maximum tensile force of the mouse achilles tendon after rupture injury; d is a graph of the effect of PD-1 antibody on maximal stress following rupture injury of the Achilles tendon in mice, where a indicates that P <0.05, ns indicates no statistical difference.
FIG. 2 is a graph showing the effect of PD-1 antibody on the formation of calcification of tendons after tendon rupture injury in mice; wherein, A is CT scanning 3D reconstructed picture of the effect of PD-1 antibody on the calcification of tendon after the injury of achilles tendon rupture, B is the statistical result picture of the effect of PD-1 antibody on the calcification of tendon after the injury of achilles tendon rupture, and in the picture, is expressed by p < 0.05.
FIG. 3 is a graph showing the HE staining results of a tissue section of a mouse with 1mm scale after injury due to achilles tendon rupture.
Detailed Description
The present invention will be described in further detail with reference to specific examples.
It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
The materials, reagents and the like used in the present examples are commercially available materials and reagents unless otherwise specified.
Example 1 Effect of PD-1 antibodies on biomechanical Properties of mice post Achilles tendon rupture injury repair
30C 57 mice (provided by the center of laboratory animals of southern medical university, raised in SPF animal room of southern hospital of southern medical university, with squirrel cage and vessels strictly disinfected, freely fed and drunk with purified water; and mice observed before experiment to have other clinical symptoms) with the age of 9 weeks are randomly divided into two groups, and an achilles tendon cutting model is adopted to simulate tendon rupture injury, and the construction method of the achilles tendon cutting model is as follows: after the mice are successfully anesthetized by injecting tribromoethanol before the operation, the mice are supine on an operating table, and the skin at the right heel is depilated and disinfected conventionally; a longitudinal incision of about 1 cm was made in the skin at the right heel under sterile conditions, exposing the sarcolemma and Achilles tendon; the medial Achilles tendon transects the metatarsus tendon and Achilles tendon, and the skin is sutured.
Administration was started the next day after the model creation (control group: 50. Mu.L PBS per mouse; experimental group: 50. Mu.g PD-1 antibody per mouse, diluted 1mg/mL of antibody stock solution before injection; the amount of PD-1 antibody injected was found by relevant literature and preliminary experiments, and no adverse reaction was caused to mice; PD-1 antibody was purchased from Bio X Cell Co., ltd., cat # BP 0146), and 1 intraperitoneal injection administration was performed every 3 days for 4 weeks. Then taking the Achilles tendon of the mouse to carry out a biomechanical tensile test, wherein the specific method comprises the following steps: mice were sacrificed by euthanasia, right lower limbs of mice were taken, rinsed with PBS, and then treated with 3D laser scanner (HandySCAN 3D) TM ) The Cross-sectional area (Cross area) of the achilles tendon is detected, a universal material testing machine (INSTRON) is used for carrying out tensile test on the achilles tendon, and the elastic Modulus (Modulus), the maximum Stress (Max Stress) and the maximum tensile Force (Max Force) are calculated.
The biomechanical property is the most important index for evaluating the tendon injury repair effect, the related biological properties of the achilles tendon of the mouse are detected by injecting the PD-1 antibody into the abdominal cavity of the mouse with the achilles tendon rupture injury, and the result is shown in figure 1, compared with a control group, the elastic modulus of the achilles tendon of an experimental group is remarkably improved (P is less than 0.05), and the PD-1 antibody can improve the elastic modulus of the achilles tendon of the mouse. Meanwhile, the cross sectional area, the maximum stress and the maximum tension of the achilles tendon of the mouse in the experimental group are not statistically different from those of the achilles tendon of the mouse in the control group, which shows that the PD-1 antibody has no influence on the cross sectional area, the maximum stress and the maximum tension of the achilles tendon of the mouse. In conclusion, the PD-1 antibody can effectively improve the biomechanical property of the mouse achilles tendon after being fractured and damaged, namely the PD-1 antibody has a better repairing effect on the mouse tendon damage.
Example 2 Effect of PD-1 antibody on tendon calcification after Achilles tendon rupture injury in mice
20C 57 mice of 9 weeks old are randomly divided into two groups, an achilles tendon cutting model is adopted to simulate tendon rupture injury, and the construction method of the achilles tendon cutting model comprises the following specific steps: after the mice are successfully anesthetized by injecting tribromoethanol before the operation, the mice are supine on an operating table, and the skin at the right heel is depilated and disinfected conventionally; making a longitudinal incision of about 1 cm in the skin at the right heel under sterile conditions to expose the sarcolemma and Achilles tendon; the medial Achilles tendon transects the metatarsus tendon and Achilles tendon, and the skin is sutured.
The administration was started the next day after the model building (control group: 50. Mu.L of PBS per mouse; experimental group: 50. Mu.g of PD-1 antibody per mouse, diluted to 1mg/mL of the antibody stock solution before the injection; the injection amount of PD-1 antibody was determined by the relevant literature and the previous experiment and does not cause adverse reaction to the mouse; PD-1 antibody was purchased from Bio X Cell Co., ltd., cat # BP 0146), and the administration was performed by intraperitoneal injection 1 time every 3 days for 4 weeks. Then, the mouse achilles tendon is taken to carry out micro-CT detection and analysis, and meanwhile, the conventional HE staining is carried out on the mouse achilles tendon tissue. The micro-CT detection specific detection steps of the mouse achilles tendon are as follows: mice were sacrificed by euthanasia, and the right lower limbs were taken, rinsed with PBS, and fixed with paraformaldehyde for 24 hours, before being stored in PBS tubes. The right lower limb is placed and fixed in a detection cabin of a small animal living body X-ray Micro-CT (Skyscan 1276) in parallel, and after scanning is finished, the calcification size is analyzed by using CTAn software.
The calcification formation is a common and serious complication after sports injury, and the micro-CT detection is performed on the achilles tendon of the mouse in the embodiment, and the result is shown in fig. 2, compared with the control group, the calcification volume in the achilles tendon of the experimental group is obviously reduced (P is less than 0.05), that is, the PD-1 antibody can obviously reduce the calcification volume after tendon injury, which indicates that the PD-1 antibody can inhibit the tendon calcification formation after tendon rupture injury. The result of HE staining of the tissues of the achilles tendon of the mouse shows that compared with the control group, the mice with tendon rupture injury are injected with the PD-1 antibody, so that no obvious ectopic ossification forming area exists in the tissues of the achilles tendon of the mouse (figure 3, wherein the inside of a dotted coil is divided into the ectopic ossification forming area), and the PD-1 antibody can obviously reduce the ectopic ossification formation after tendon injury.
The embodiments of the present invention have been described in detail with reference to the drawings, but the present invention is not limited to the embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the gist of the present invention. Furthermore, the embodiments of the present invention and features of the embodiments may be combined with each other without conflict.
Claims (7)
- Use of an antibody to PD-1, purchased from BioXCell, inc, under the trade designation BP0146d, for the manufacture of a medicament for the prevention and/or treatment of tendon injury.
- Use of an antibody to PD-1, purchased from BioXCell, having the cargo number BP0146d, for the manufacture of a medicament for inhibiting the formation of calcification of injured tendon tissue.
- 3. The use of claim 2, wherein the tendon comprises at least one of an achilles tendon, a rotator cuff, and a supraspinatus.
- Use of a PD-1 antibody, purchased from BioXCell, having the cat number BP0146d, for the preparation of a medicament for improving the biomechanical properties of injured tendons.
- 5. The use of claim 4, wherein the tendon comprises at least one of an achilles tendon, a rotator cuff, and a supraspinatus.
- Use of a PD-1 antibody, purchased from BioXCell, inc, under the designation BP0146d, for the preparation of a medicament for inhibiting ectopic ossification formation after tendon injury.
- 7. The use of claim 6, wherein the tendon comprises at least one of the Achilles tendon, rotator cuff, supraspinatus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210724451.4A CN114939161B (en) | 2022-06-24 | 2022-06-24 | Application of PD-1 antibody in preparation of medicine for treating tendon injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210724451.4A CN114939161B (en) | 2022-06-24 | 2022-06-24 | Application of PD-1 antibody in preparation of medicine for treating tendon injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114939161A CN114939161A (en) | 2022-08-26 |
| CN114939161B true CN114939161B (en) | 2023-02-28 |
Family
ID=82910314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210724451.4A Active CN114939161B (en) | 2022-06-24 | 2022-06-24 | Application of PD-1 antibody in preparation of medicine for treating tendon injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114939161B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117442703A (en) * | 2023-11-29 | 2024-01-26 | 南方医科大学南方医院 | Application of Elamipretide in preparation of drugs for preventing and/or treating tendon injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111363041A (en) * | 2016-03-23 | 2020-07-03 | 迈博斯生物医药(苏州)有限公司 | Novel anti-PD-L1 antibodies |
| CN113694204A (en) * | 2021-08-26 | 2021-11-26 | 南方医科大学南方医院 | Composition for treating osteomyelitis and application thereof |
-
2022
- 2022-06-24 CN CN202210724451.4A patent/CN114939161B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111363041A (en) * | 2016-03-23 | 2020-07-03 | 迈博斯生物医药(苏州)有限公司 | Novel anti-PD-L1 antibodies |
| CN113694204A (en) * | 2021-08-26 | 2021-11-26 | 南方医科大学南方医院 | Composition for treating osteomyelitis and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| PD-1 and Its Ligands in Tolerance and Immunity;Mary E. Keir等;《Annu. Rev. Immunol》;20080102;第26卷;第677-704页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114939161A (en) | 2022-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dyson et al. | Suspensory ligament desmitis | |
| KR20120090044A (en) | Low frequency glatiramer acetate therapy | |
| Radzik et al. | Prospects of epileptogenesis prevention | |
| CN114939161B (en) | Application of PD-1 antibody in preparation of medicine for treating tendon injury | |
| André Desrochers | Diseases of the tendons and tendon sheaths | |
| JP6180417B2 (en) | Use of compounds for the manufacture of therapeutic agents for heart failure or neuronal damage | |
| CN113288904B (en) | Application of Mitoquinone in preparation of medicine for preventing and/or treating sports injury | |
| US20220096428A1 (en) | Method for Treating Osteoarthritis Pain by Administering Resiniferatoxin | |
| Vellingiri et al. | A Prospective Study Comparing the Efficacy of Local Injection of Platelet-Rich Plasma (PRP) vs Methylprednisolone in Plantar Fasciitis | |
| Kim et al. | Synergetic effects of shock waves with polydeoxyribonucleotides on rotator cuff tendon tear in a rabbit model | |
| CN112353794A (en) | Pharmaceutical composition for treating cerebral infarction diseases and application thereof | |
| CN113288890B (en) | Application of N-acetyl-L-cysteine in preparation of medicine for preventing and/or treating sports injury | |
| Kemp et al. | Infectious diseases: echinococcosis (hydatid disease) | |
| Kim et al. | Infectious Achilles Tendinitis After Local Injection of Human Placental Extracts: A Case Report | |
| RU2293561C1 (en) | Method for predicting acute appendicitis in pregnant women | |
| RU2722162C1 (en) | Method of treating tendon-ligamentous apparatus injuries in horses | |
| RU2778611C1 (en) | Method for comprehensive treatment of degenerative dystrophic diseases of the musculoskeletal system | |
| CN117442703A (en) | Application of Elamipretide in preparation of drugs for preventing and/or treating tendon injury | |
| Kawcak et al. | Lameness of the Proximal Limb: THE CARPUS | |
| Rajadurai | Management of Dequervain’s tenosynovitis with splint and intra-sheath steroid: A comparative study | |
| RU2447894C1 (en) | Veterinary homeopathic agent for external application in musculoskeletal diseases | |
| Spengane et al. | Treatment of urticarial vasculitis with omalizumab | |
| De Veirman | The pharmacological treatment of navicular syndrome in horses | |
| Rathod et al. | Minimally invasive treatment of a complex tibial plateau fracture with diaphyseal extension in a patient with uncontrolled diabetes mellitus: a case report and review of literature | |
| JOHNSON JR et al. | Treatment of benign giant-cell tumor in the lower third of the femur by curettage and" telescoping" the fragments of bone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |